Ayala Pharmaceuticals, Inc. (ADXS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
9 DEER PARK DRIVE MONMOUTH JUNCTION, NJ 08852 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 10/31/2022 Q4 | 7/31/2022 Q3 | 4/30/2022 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 2,225 | 7,185 | 16,947 | 25,208 | 28,150 | 32,085 | |||
| Cash and cash equivalents | 2,123 | 7,079 | 16,839 | 25,208 | 28,150 | 32,085 | |||
| Short-term investments | 102 | 106 | 108 | ||||||
| Receivables | 4 | ||||||||
| Prepaid expense | |||||||||
| Other undisclosed current assets | 2,327 | 2,371 | 1,310 | 551 | 1,667 | 2,092 | |||
| Total current assets: | 4,552 | 9,556 | 18,261 | 25,759 | 29,817 | 34,177 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,276 | 1,390 | 1,442 | 12 | 19 | 26 | |||
| Property, plant and equipment | 845 | 882 | 950 | 38 | 73 | 84 | |||
| Intangible assets, net (including goodwill) | 107 | 115 | 130 | 110 | 181 | 3,220 | |||
| Goodwill | |||||||||
| Intangible assets, net (excluding goodwill) | 107 | 115 | 130 | 110 | 181 | 3,220 | |||
| Other noncurrent assets | 212 | 11 | 11 | 11 | |||||
| Other undisclosed noncurrent assets | 201 | 208 | |||||||
| Total noncurrent assets: | 2,429 | 2,595 | 2,734 | 171 | 284 | 3,341 | |||
| TOTAL ASSETS: | 6,981 | 12,151 | 20,995 | 25,930 | 30,101 | 37,518 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 7,843 | 7,726 | 7,894 | 2,172 | 1,716 | 1,851 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | ✕ | 116 | 74 | ||
| Accounts payable | 5,056 | 4,420 | 4,140 | 22 | 90 | 39 | |||
| Accrued liabilities | 2,787 | 3,306 | 3,754 | 2,150 | 1,510 | 1,738 | |||
| Other undisclosed accounts payable and accrued liabilities | |||||||||
| Other undisclosed current liabilities | 684 | 701 | 1,939 | 131 | 190 | 516 | |||
| Total current liabilities: | 8,527 | 8,427 | 9,833 | 2,303 | 1,906 | 2,367 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 2,068 | ||||||||
| Long-term debt, excluding current maturities | 2,068 | ||||||||
| Liabilities, other than long-term debt | 932 | 1,000 | 1,410 | ||||||
| Operating lease, liability | 932 | 1,000 | 1,410 | ||||||
| Other undisclosed noncurrent liabilities | 1,695 | 1,715 | 77 | ||||||
| Total noncurrent liabilities: | 4,695 | 2,715 | 1,487 | ||||||
| Total liabilities: | 13,222 | 11,142 | 11,320 | 2,303 | 1,906 | 2,367 | |||
| Equity | |||||||||
| Equity, attributable to parent | (6,241) | 1,009 | 9,675 | 23,627 | 28,195 | 35,151 | |||
| Common stock | 5 | 5 | 5 | 2 | 2 | 2 | |||
| Additional paid in capital | 166,307 | 166,218 | 166,185 | 466,584 | 466,561 | 466,554 | |||
| Accumulated deficit | (172,553) | (165,214) | (156,515) | (442,959) | (438,368) | (431,405) | |||
| Total equity: | (6,241) | 1,009 | 9,675 | 23,627 | 28,195 | 35,151 | |||
| TOTAL LIABILITIES AND EQUITY: | 6,981 | 12,151 | 20,995 | 25,930 | 30,101 | 37,518 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 10/31/2022 Q4 | 7/31/2022 Q3 | 4/30/2022 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 9 | 4 | 250 | |||||
| Cost of revenue (Cost of Goods and Services Sold) | (9) | (4) | ||||||
| Gross profit: | 250 | |||||||
| Operating expenses | (7,131) | (8,486) | (11,869) | (4,853) | (7,291) | (3,252) | ||
| Operating loss: | (7,131) | (8,486) | (11,869) | (4,853) | (7,291) | (3,002) | ||
| Nonoperating income (expense) | (143) | (86) | (6) | 2 | (1) | |||
| Other nonoperating income (expense) | (6) | 2 | (1) | |||||
| Loss from continuing operations before equity method investments, income taxes: | (7,274) | (8,572) | (11,869) | (4,859) | (7,289) | (3,003) | ||
| Other undisclosed income from continuing operations before income taxes | 301 | 268 | 326 | 613 | ||||
| Loss from continuing operations before income taxes: | (7,274) | (8,572) | (11,568) | (4,591) | (6,963) | (2,390) | ||
| Income tax expense (benefit) | (65) | (127) | 4,207 | (50) | ||||
| Loss from continuing operations: | (7,339) | (8,699) | (7,361) | (4,591) | (6,963) | (2,440) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | (6,963) | (2,440) | |
| Net loss attributable to parent: | (7,339) | (8,699) | (7,361) | (4,591) | (6,963) | (2,440) | ||
| Preferred stock dividends and other adjustments | (1,025) | |||||||
| Net loss available to common stockholders, diluted: | (7,339) | (8,699) | (7,361) | (4,591) | (6,963) | (3,465) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 10/31/2022 Q4 | 7/31/2022 Q3 | 4/30/2022 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (7,339) | (8,699) | (7,361) | (4,591) | (6,963) | (2,440) | ||
| Comprehensive loss, net of tax, attributable to parent: | (7,339) | (8,699) | (7,361) | (4,591) | (6,963) | (2,440) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.